k141_74171_15	SARG|gb|APB03219.1|ARO:3003986|TaeA	29.9	655	759	648	1.70e-85	283
k141_74171_15	SARG|gb|AEO25219.1|ARO:3004651|lin	25.0	567	759	523	4.41e-35	139
k141_74171_15	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.6	624	759	550	3.51e-34	137
k141_74171_15	SARG|DAC81085.1	31.1	299	759	486	1.17e-30	125
k141_74171_15	SARG|AAA50325	31.0	329	759	569	1.47e-30	126
k141_74171_15	SARG|gb|NP_388442.1|ARO:3004476|vmlR	30.7	322	759	547	9.31e-30	123
k141_74171_15	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	35.3	221	759	485	1.70e-28	119
k141_74171_15	SARG|gi|488231473|ref|WP_002302681.1|	34.4	227	759	492	1.83e-28	119
k141_74171_15	SARG|gi|488216250|ref|WP_002287458.1|	34.4	227	759	492	1.83e-28	119
k141_74171_15	SARG|gi|488247627|ref|WP_002318835.1|	34.4	227	759	492	1.83e-28	119
k141_74171_32	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.3	233	257	228	3.82e-59	186
k141_74171_32	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.8	230	257	232	1.77e-55	177
k141_74171_32	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.8	230	257	232	1.77e-55	177
k141_74171_32	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.5	229	257	219	2.17e-53	171
k141_74171_32	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.2	233	257	231	6.21e-53	170
k141_74171_32	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.3	230	257	231	6.21e-53	170
k141_74171_32	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.0	230	257	229	8.27e-53	170
k141_74171_32	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.6	229	257	231	1.75e-52	169
k141_74171_32	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	229	257	231	1.75e-52	169
k141_74171_32	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.7	230	257	231	2.48e-52	169
k141_74171_56	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.5	218	426	343	2.25e-26	107
k141_74171_56	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.6	265	426	579	7.26e-19	87.8
k141_74171_56	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	29.3	273	426	579	3.08e-18	85.9
k141_74171_56	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.7	240	426	574	2.87e-13	70.5
k141_74171_56	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	28.9	204	426	528	1.45e-06	49.3
k141_74171_60	NCBI|WP_018211347.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	34.5	397	396	345	4.51e-72	228
k141_74171_60	SARG|AF277571.gene.p01	35.2	398	396	343	8.46e-72	227
k141_74171_60	SARG|ACM47287	36.5	400	396	343	1.19e-71	227
k141_74171_60	SARG|AAR37060	36.2	401	396	343	1.68e-71	226
k141_74171_60	NCBI|WP_011029110.1|1|1|vanA-Sc|vanA-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanA-Sc|AMR|glycopeptide	36.5	395	396	346	1.83e-71	226
k141_74171_60	SARG|gi|696673086|ref|WP_033144146.1|	35.4	398	396	343	2.37e-71	226
k141_74171_60	megares|MEG_7340|Drugs|Glycopeptide|VanA-type_resistance_protein|VANA_1	36.2	395	396	346	5.14e-71	225
k141_74171_60	megares|MEG_7344|Drugs|Glycopeptide|VanA-type_resistance_protein|VANA_2	36.2	395	396	352	6.11e-71	225
k141_74171_60	SARG|ABS72058	36.2	398	396	343	9.37e-71	224
k141_74171_60	SARG|gi|1002798395|gb|AMN85478.1|	35.4	398	396	343	1.32e-70	224
k141_10060_17	SARG|YP_001419928	36.4	456	511	477	1.95e-87	276
k141_10060_17	SARG|gi|1030030526|gb|ANF35167.1|	36.4	456	511	477	2.74e-87	275
k141_10060_17	SARG|gi|371566923|emb|CCF03773.1|	36.4	456	511	477	5.43e-87	275
k141_10060_17	SARG|gi|494883168|ref|WP_007609218.1|	36.4	456	511	479	5.74e-87	275
k141_10060_17	SARG|gi|566055109|gb|AHC40857.1|	36.4	456	511	477	7.64e-87	274
k141_10060_17	SARG|gi|1036324608|gb|OAZ67878.1|	36.0	456	511	477	1.51e-86	273
k141_10060_17	SARG|gi|503878543|ref|WP_014112537.1|	37.1	456	511	477	2.99e-86	273
k141_10060_17	SARG|gi|542004148|gb|ERH50104.1|	36.2	456	511	477	4.21e-86	272
k141_10060_17	SARG|gi|393806119|gb|EJD67473.1|	36.2	456	511	477	5.93e-86	272
k141_10060_17	SARG|gi|1007411670|gb|AMQ72759.1|	36.2	456	511	477	8.34e-86	271
k141_5143_20	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	43.6	691	713	703	1.33e-171	507
k141_44598_2	SARG|gi|447057509|ref|WP_001134765.1|	33.2	217	376	309	1.57e-25	103
k141_44598_2	SARG|gi|507055561|ref|WP_016126482.1|	32.3	217	376	309	2.16e-25	103
k141_44598_2	SARG|gi|488068784|ref|WP_002140181.1|	33.2	217	376	309	2.16e-25	103
k141_44598_2	SARG|gi|447057510|ref|WP_001134766.1|	32.7	217	376	309	2.97e-25	103
k141_44598_2	SARG|gi|488067981|ref|WP_002139378.1|	32.7	217	376	309	5.63e-25	102
k141_44598_2	SARG|gi|487936534|ref|WP_002010000.1|	32.7	217	376	309	5.63e-25	102
k141_44598_2	SARG|gi|507023808|ref|WP_016095885.1|	32.3	217	376	309	7.75e-25	102
k141_44598_2	SARG|gi|488120365|ref|WP_002191762.1|	30.9	217	376	309	2.02e-24	100
k141_44598_2	SARG|gi|488053456|ref|WP_002124853.1|	32.3	217	376	309	2.02e-24	100
k141_44598_2	SARG|gi|445996719|ref|WP_000074574.1|	32.7	217	376	309	2.77e-24	100
k141_74574_50	SARG|YP_001487997	38.1	286	295	292	2.14e-40	141
k141_74574_50	SARG|ZP_03054084	37.8	286	295	302	2.71e-40	141
k141_74574_50	SARG|Q880L3	32.7	275	295	276	4.31e-39	137
k141_74574_50	SARG|ZP_04055725	35.2	287	295	283	1.01e-38	136
k141_74574_50	SARG|Q4KC13	33.7	273	295	276	1.19e-38	136
k141_74574_50	SARG|YP_274443	33.5	275	295	277	2.40e-38	135
k141_74574_50	SARG|YP_236080	33.1	275	295	276	4.62e-38	134
k141_74574_50	SARG|YP_001187667	32.8	274	295	276	4.62e-38	134
k141_74574_50	SARG|ZP_04589788	33.5	275	295	276	6.48e-38	134
k141_74574_50	SARG|YP_002800019	35.1	288	295	277	9.32e-38	134
k141_5729_71	SARG|gi|851922185|ref|WP_048218206.1|	43.8	226	227	648	2.83e-47	164
k141_5729_71	SARG|gi|949718947|ref|WP_057063453.1|	43.8	226	227	648	2.83e-47	164
k141_5729_71	SARG|gi|696375069|ref|WP_032949617.1|	43.8	226	227	648	2.83e-47	164
k141_5729_71	SARG|gi|489127020|ref|WP_003036815.1|	43.8	226	227	648	2.83e-47	164
k141_5729_71	SARG|gi|487407385|ref|WP_001675419.1|	42.5	226	227	648	7.50e-47	162
k141_5729_71	SARG|gi|487661511|ref|WP_001751648.1|	42.5	226	227	648	7.50e-47	162
k141_5729_71	SARG|gi|446048030|ref|WP_000125885.1|	42.5	226	227	648	7.50e-47	162
k141_5729_71	SARG|YP_002214869	42.5	226	227	648	7.50e-47	162
k141_5729_71	SARG|gi|696361545|ref|WP_032936694.1|	42.9	226	227	648	7.50e-47	162
k141_5729_71	SARG|gi|489936909|ref|WP_003840216.1|	42.9	226	227	648	7.50e-47	162
k141_25586_13	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.1	208	264	255	2.30e-28	107
k141_25586_13	SARG|gi|1028085645|ref|WP_063844178.1|	34.6	217	264	646	1.70e-26	107
k141_25586_13	SARG|gi|1028176459|ref|WP_063924113.1|	34.6	217	264	646	1.70e-26	107
k141_25586_13	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.5	213	264	655	1.66e-08	53.9
k141_25586_13	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.5	213	264	655	1.66e-08	53.9
k141_25586_13	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.5	213	264	655	7.12e-08	52.0
k141_25586_13	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.1	213	264	655	1.70e-07	50.8
k141_25586_13	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.1	213	264	655	1.70e-07	50.8
k141_25586_13	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.1	213	264	655	1.70e-07	50.8
k141_25586_13	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.1	213	264	655	1.70e-07	50.8
k141_25586_14	SARG|gi|497748188|ref|WP_010062372.1|	31.1	228	262	605	2.17e-16	77.4
k141_25586_14	SARG|gi|1045390184|ref|WP_065479071.1|	30.6	222	262	605	2.93e-16	77.0
k141_25586_14	SARG|gi|928900436|ref|WP_053931243.1|	30.6	219	262	600	7.19e-16	75.9
k141_25586_14	SARG|gi|664579989|ref|WP_031094015.1|	30.6	219	262	601	7.19e-16	75.9
k141_25586_14	SARG|gi|664352659|ref|WP_030880307.1|	31.1	222	262	601	9.71e-16	75.5
k141_25586_14	SARG|gi|662754041|ref|WP_030125200.1|	31.1	222	262	601	9.71e-16	75.5
k141_25586_14	SARG|gi|664100597|ref|WP_030638327.1|	31.1	222	262	601	9.71e-16	75.5
k141_25586_14	SARG|gi|505389066|ref|WP_015576168.1|	31.1	222	262	601	9.71e-16	75.5
k141_25586_14	SARG|gi|503923650|ref|WP_014157644.1|	31.1	222	262	601	9.71e-16	75.5
k141_25586_14	SARG|gi|764446018|ref|WP_044369325.1|	30.2	222	262	605	9.74e-16	75.5
k141_25586_23	SARG|gi|498467693|ref|WP_010773049.1|	29.2	329	453	700	2.21e-27	114
k141_25586_23	SARG|FJ872411.1.gene43.p01	29.6	321	453	702	3.11e-26	110
k141_25586_38	SARG|gi|502669352|ref|WP_012905216.1|	46.4	220	261	648	2.15e-62	206
k141_25586_38	SARG|gi|754927849|ref|WP_042284850.1|	45.0	240	261	648	8.17e-62	204
k141_25586_38	SARG|gi|493734654|ref|WP_006683876.1|	45.0	240	261	648	1.59e-61	203
k141_25586_38	SARG|gi|968563772|ref|WP_058587854.1|	46.4	220	261	648	4.33e-61	202
k141_25586_38	SARG|gi|757782629|ref|WP_043001213.1|	46.4	220	261	648	4.33e-61	202
k141_25586_38	SARG|gi|992390012|ref|WP_061077002.1|	46.4	220	261	648	4.33e-61	202
k141_25586_38	SARG|gi|763407609|ref|WP_044264203.1|	46.4	220	261	648	4.33e-61	202
k141_25586_38	SARG|gi|823326845|ref|WP_047080664.1|	47.3	220	261	648	6.04e-61	202
k141_25586_38	SARG|gi|835233765|ref|WP_047410073.1|	46.8	220	261	648	8.43e-61	201
k141_25586_38	SARG|gi|754951242|ref|WP_042307417.1|	46.8	220	261	648	8.43e-61	201
k141_25586_40	SARG|gi|766961649|ref|WP_044860626.1|	41.2	97	520	648	1.26e-13	72.4
k141_25586_40	SARG|gi|896325272|ref|WP_049294291.1|	41.8	98	520	648	1.26e-13	72.4
k141_25586_40	SARG|gi|639216333|ref|WP_024554080.1|	41.8	98	520	648	1.26e-13	72.4
k141_25586_40	SARG|gi|835742181|ref|WP_047642376.1|	40.2	97	520	646	2.20e-13	71.6
k141_25586_40	SARG|gi|693066875|ref|WP_032232318.1|	41.2	97	520	648	2.20e-13	71.6
k141_25586_40	SARG|gi|693063780|ref|WP_032229718.1|	41.2	97	520	648	2.20e-13	71.6
k141_25586_40	SARG|gi|446110340|ref|WP_000188195.1|	41.2	97	520	648	2.20e-13	71.6
k141_25586_40	SARG|gi|639225329|ref|WP_024561799.1|	41.2	97	520	648	2.92e-13	71.2
k141_25586_40	SARG|gi|693106883|ref|WP_032260279.1|	40.4	99	520	648	2.92e-13	71.2
k141_25586_40	SARG|gi|1016544759|ref|WP_063115144.1|	40.4	99	520	648	2.92e-13	71.2
k141_25586_53	SARG|gi|749639729|ref|WP_040241690.1|	43.4	226	262	646	4.08e-44	156
k141_25586_53	SARG|gi|1016069923|ref|WP_062914571.1|	43.4	226	262	646	5.36e-43	153
k141_25586_53	SARG|gi|516510995|ref|WP_017899433.1|	43.4	226	262	646	5.36e-43	153
k141_25586_53	SARG|gi|1031822889|ref|WP_064150402.1|	43.4	226	262	646	7.39e-43	153
k141_25586_53	SARG|gi|490306253|ref|WP_004201358.1|	43.4	226	262	646	7.39e-43	153
k141_25586_53	SARG|gi|950164608|ref|WP_057214157.1|	43.4	226	262	646	7.39e-43	153
k141_25586_53	SARG|gi|694113305|ref|WP_032455256.1|	43.4	226	262	646	7.39e-43	153
k141_25586_53	SARG|gi|764951644|ref|WP_044521907.1|	43.4	226	262	646	7.39e-43	153
k141_25586_53	SARG|gi|896073592|ref|WP_049116987.1|	43.4	226	262	646	7.39e-43	153
k141_25586_53	SARG|gi|927316447|ref|WP_053810605.1|	43.4	226	262	646	7.39e-43	153
k141_25586_66	megares|MEG_2865|Drugs|Phenicol|Chloramphenicol_hydrolase|ESTD_1	33.2	253	435	310	2.10e-33	126
k141_25586_66	NCBI|WP_011906899.1|1|1|estDL136|estDL136||2|CHLORAMPHENICOL/FLORFENICOL|PHENICOL|phenicol_hydrolase|AMR|phenicol	34.1	261	435	308	1.72e-29	115
k141_25586_76	SARG|NP_348076	27.6	680	708	652	1.91e-75	254
k141_25586_76	SARG|YP_002850805	27.6	696	708	652	1.37e-74	252
k141_25586_76	SARG|ZP_02632674	27.0	705	708	660	5.96e-73	248
k141_25586_76	SARG|ZP_02952732	27.2	696	708	652	1.35e-72	247
k141_25586_76	SARG|L42544.gene.p01	28.0	683	708	651	4.91e-72	245
k141_25586_76	SARG|L20800.gene.p01	27.2	696	708	652	5.01e-72	245
k141_25586_76	SARG|AAV80410	28.0	683	708	651	9.45e-72	244
k141_25586_76	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	27.4	682	708	639	1.88e-68	235
k141_25586_76	SARG|ABN80187	26.4	701	708	640	2.65e-68	235
k141_25586_76	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.8	691	708	641	7.18e-68	234
k141_25586_77	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	34.9	129	400	639	2.57e-13	70.5
k141_25586_82	megares|MEG_8037|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|CRCB_1	35.4	113	122	137	2.36e-13	61.2
k141_25586_82	SARG|gb|CCN31428.1|ARO:3005049|CrcB	35.4	113	122	137	2.36e-13	61.2
k141_45103_3	megares|MEG_8243|Drugs|MLS|MLS_resistance_MFS_efflux_pumps|MEFD_1	26.9	432	497	399	1.91e-36	138
k141_45103_3	SARG|QHW12307.1	26.9	432	497	399	1.91e-36	138
k141_45103_3	ResF|mdt(A)_1_X92946_1	26.4	425	497	418	5.01e-36	137
k141_45103_3	NCBI|WP_101035418.1|1|1|mef(F)|mef(F)|efflux|2|AZITHROMYCIN/ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(F)|AMR|macrolide	26.6	425	497	397	2.19e-34	132
k141_45103_3	SARG|gb|QNR09091.1|ARO:3007044|mefF	26.6	425	497	397	2.19e-34	132
k141_45103_3	SARG|gb|ACJ63262.1|ARO:3003107|mefB	24.8	419	497	409	2.72e-31	124
k141_45103_4	SARG|AE016830.1.gene424.p01	40.7	425	684	505	6.27e-110	340
k141_45103_4	SARG|NC_002951.3237948.p01	38.5	413	684	643	8.79e-91	295
k141_45103_4	SARG|NC_002951.3237419.p01	38.5	405	684	480	2.86e-89	286
k141_45103_4	SARG|NC_002951.3238155.p01	37.0	395	684	465	3.78e-83	269
k141_45103_4	SARG|NC_009641.5331418.p01	36.5	381	684	452	9.28e-78	254
k141_45103_4	SARG|gi|503878543|ref|WP_014112537.1|	36.5	400	684	477	5.16e-76	251
k141_45103_4	SARG|gi|498485855|ref|WP_010787543.1|	36.3	416	684	476	2.67e-75	249
k141_45103_4	SARG|gi|1036324608|gb|OAZ67878.1|	36.3	400	684	477	5.52e-74	245
k141_45103_4	SARG|ZP_03589930	36.5	400	684	477	1.50e-73	244
k141_45103_4	SARG|YP_001419928	36.3	397	684	477	1.50e-73	244
k141_45103_49	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.9	576	653	575	2.16e-116	358
k141_45103_49	SARG|gb|AAK76137.1|ARO:3000024|patA	35.6	576	653	564	3.53e-107	334
k141_45103_49	SARG|gi|664556405|ref|WP_031071225.1|	29.7	600	653	602	2.09e-64	222
k141_45103_49	SARG|gi|639892676|ref|WP_024755698.1|	29.1	612	653	631	3.64e-64	222
k141_45103_49	SARG|gi|1011069317|ref|WP_062010695.1|	28.9	592	653	614	3.66e-64	222
k141_45103_49	SARG|gi|1033151784|ref|WP_064457526.1|	28.9	592	653	614	5.07e-64	221
k141_45103_49	SARG|gi|947982677|ref|WP_056642336.1|	29.1	612	653	626	8.81e-64	221
k141_45103_49	SARG|gi|664304639|ref|WP_030834011.1|	28.9	592	653	614	9.73e-64	221
k141_45103_49	SARG|gi|926400371|ref|WP_053728483.1|	29.0	599	653	603	1.09e-63	220
k141_45103_49	SARG|gi|944009777|ref|WP_055601444.1|	28.8	611	653	628	1.75e-63	220
k141_45103_50	SARG|gb|AAK76136.1|ARO:3000025|patB	31.2	658	672	588	1.95e-94	302
k141_45103_50	SARG|gi|664304639|ref|WP_030834011.1|	29.2	665	672	614	5.69e-69	235
k141_45103_50	SARG|gi|1033151784|ref|WP_064457526.1|	29.0	665	672	614	2.11e-68	234
k141_45103_50	SARG|gi|987887954|ref|WP_060953374.1|	29.0	665	672	614	2.11e-68	234
k141_45103_50	SARG|gi|1011069317|ref|WP_062010695.1|	29.0	665	672	614	2.93e-68	233
k141_45103_50	SARG|gb|CDO61516.1|ARO:3003949|efrB	50.0	212	672	362	5.14e-65	218
k141_45103_50	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.4	366	672	664	1.87e-64	224
k141_45103_50	SARG|gi|948137056|ref|WP_056795395.1|	47.0	249	672	602	1.10e-63	221
k141_45103_50	SARG|gi|926400371|ref|WP_053728483.1|	46.7	257	672	603	2.09e-62	217
k141_45103_50	SARG|gi|496018010|ref|WP_008742581.1|	47.3	241	672	623	2.20e-62	218
k141_45103_58	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	91.6	1102	1104	1107	0.0	2079
k141_45103_58	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	91.6	1102	1104	1107	0.0	2079
k141_45103_58	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	33.0	1064	1104	1024	1.08e-194	591
k141_45103_58	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.0	1064	1104	1024	1.08e-194	591
k141_45103_58	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	33.0	1058	1104	1024	1.66e-193	588
k141_45103_58	SARG|gb|CAA53189|ARO:3000521|mupA	33.0	1058	1104	1024	1.66e-193	588
k141_45103_58	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	32.0	1076	1104	1033	2.67e-186	569
k141_45103_58	SARG|gb|AEY83581|ARO:3000510|mupB	32.0	1076	1104	1033	2.67e-186	569
k141_45103_98	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.0	231	244	219	5.14e-51	164
k141_45103_98	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	39.6	240	244	230	2.85e-47	155
k141_45103_98	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.6	235	244	228	6.02e-46	152
k141_45103_98	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.6	237	244	231	1.31e-45	151
k141_45103_98	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.1	245	244	232	3.78e-45	150
k141_45103_98	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.1	245	244	232	3.78e-45	150
k141_45103_98	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	42.0	243	244	231	7.33e-45	149
k141_45103_98	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.1	240	244	233	4.84e-43	144
k141_45103_98	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	35.7	241	244	235	5.11e-43	144
k141_45103_98	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.9	243	244	231	1.29e-42	143
k141_35351_41	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	29.8	376	489	633	2.41e-24	105
k141_35351_41	ResF|penA_1_AF515059_1	26.9	442	489	581	3.74e-18	86.3
k141_35351_43	CARD|gb|WKR28567.1|ARO:3007678|IreK	34.7	639	691	718	9.42e-84	278
k141_11080_29	SARG|gi|740152780|ref|WP_037997109.1|	27.2	235	339	322	1.25e-19	87.0
k141_11080_29	SARG|NP_878015	25.9	263	339	322	8.09e-19	84.7
k141_11080_29	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	25.5	239	339	343	2.54e-18	83.6
k141_11080_29	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	25.5	239	339	348	2.66e-18	83.6
k141_11080_29	SARG|AAY52004	26.0	235	339	322	2.80e-18	83.2
k141_11080_29	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	25.9	239	339	322	3.81e-18	82.8
k141_11080_29	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	26.4	239	339	237	2.72e-17	79.0
k141_11080_29	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	26.3	240	339	351	1.95e-16	78.2
k141_11080_38	megares|MEG_3000|Drugs|Fosfomycin|Fosfomycin_thiol_transferases|FOSA_1	33.3	87	135	132	3.11e-06	42.7
k141_11080_38	NCBI|WP_005475717.1|1|1|fos-Vibrio|fos-Vibrio|thiol_transferase|2|phosphonic	33.3	87	135	132	3.11e-06	42.7
k141_11080_85	ResF|mre(A)_1_U92073_1	28.4	342	375	310	9.88e-31	118
k141_11080_85	SARG|gb|AAB64408.1|ARO:3007050|mreA	28.4	342	375	311	1.01e-30	118
k141_11080_96	SARG|gb|ALV80601.1|ARO:3003801|bcr-1	34.2	117	518	402	6.26e-10	60.1
k141_75362_10	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.9	219	232	204	7.55e-18	77.8
k141_75362_17	SARG|NP_044444	25.7	362	397	391	2.98e-26	107
k141_75362_17	SARG|AF024666.2.gene33.p01	25.4	362	397	391	5.58e-26	107
k141_75362_17	SARG|YP_251195	25.4	362	397	391	1.04e-25	106
k141_75362_17	SARG|gi|2708772|gb|AAB96371.1|	25.1	362	397	391	3.64e-25	104
k141_75362_22	CARD|gb|AEX49906.1|ARO:3003583|basS	27.6	185	395	477	6.11e-12	65.9
k141_75362_22	CARD|gb|ADM92606.1|ARO:3000549|adeS	29.4	109	395	361	7.55e-08	52.8
k141_75362_32	SARG|CAL48457	37.2	188	221	183	1.10e-31	113
k141_75362_32	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	44.0	141	221	162	6.87e-31	110
k141_75362_32	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	35.4	164	221	167	6.91e-25	95.1
k141_75362_32	SARG|CAE53424	35.8	173	221	169	7.27e-25	95.1
k141_75362_32	megares|MEG_8062|Drugs|Trimethoprim|Dihydrofolate_reductase|DFRA_1	33.7	169	221	195	9.74e-25	95.5
k141_75362_32	SARG|gb|WP_000949574.1|ARO:3005348|DfrA36	33.7	169	221	195	9.74e-25	95.5
k141_75362_32	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	34.7	173	221	166	1.87e-24	94.0
k141_75362_32	SARG|gb|ABO40886.1|ARO:3004645|dfrI	36.4	129	221	191	2.78e-22	89.0
k141_75362_32	SARG|ACR66838	36.5	126	221	165	4.17e-22	87.8
k141_75362_32	NCBI|WP_071846282.1|1|1|dfrA12|dfrA12|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA12|AMR|diaminopyrimidine	35.7	126	221	165	8.21e-22	87.0
k141_11949_8	SARG|AUI09862.1	40.5	284	292	287	3.45e-48	161
k141_11949_8	SARG|AJ459418.gene.p01	32.0	266	292	263	1.93e-28	108
k141_11949_8	SARG|gi|970263436|ref|WP_058647620.1|	31.6	266	292	263	3.85e-27	105
k141_11949_8	SARG|gi|446966005|ref|WP_001043261.1|	33.2	262	292	271	2.39e-25	100
k141_11949_8	SARG|gi|504199703|ref|WP_014386805.1|	32.0	222	292	271	8.90e-25	99.4
k141_11949_8	SARG|gi|499772318|ref|WP_011453052.1|	32.7	226	292	272	9.07e-25	99.4
k141_11949_8	SARG|gi|691032885|ref|WP_031987899.1|	33.3	222	292	271	1.24e-24	99.0
k141_11949_8	SARG|gi|1028099083|ref|WP_063855540.1|	33.3	222	292	271	1.72e-24	98.6
k141_11949_8	SARG|gi|487670925|ref|WP_001756235.1|	33.3	222	292	271	1.72e-24	98.6
k141_11949_8	SARG|gi|499192666|ref|WP_010890206.1|	33.3	222	292	271	1.72e-24	98.6
k141_11949_12	SARG|gb|APB03219.1|ARO:3003986|TaeA	38.6	508	560	648	3.01e-112	347
k141_11949_12	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	3.83e-73	244
k141_11949_12	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.1	527	560	655	1.45e-72	243
k141_11949_12	SARG|gb|AKA86814|ARO:3003746|optrA	31.1	527	560	655	1.45e-72	243
k141_11949_14	SARG|gi|696420214|ref|WP_032990021.1|	36.9	222	289	647	1.74e-28	113
k141_11949_14	SARG|gi|507044560|ref|WP_016115614.1|	26.6	214	289	306	8.88e-20	86.3
k141_11949_14	SARG|ZP_04081918	26.2	214	289	306	1.68e-19	85.5
k141_11949_14	SARG|gi|446026113|ref|WP_000103968.1|	27.9	204	289	306	1.68e-19	85.5
k141_11949_14	SARG|gi|447195836|ref|WP_001273092.1|	25.7	214	289	306	4.35e-19	84.3
k141_11949_14	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	26.8	205	289	343	5.78e-18	81.6
k141_11949_14	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	23.6	216	289	307	2.66e-17	79.3
k141_11949_14	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.8	205	289	664	7.69e-14	70.5
k141_11949_14	SARG|gi|953808775|ref|WP_058042812.1|	29.9	234	289	608	2.41e-13	68.9
k141_11949_14	SARG|gi|496018010|ref|WP_008742581.1|	28.4	225	289	623	1.43e-12	66.6
k141_11949_17	SARG|gi|447195835|ref|WP_001273091.1|	28.0	225	518	306	4.74e-13	68.9
k141_11949_17	SARG|gi|447195836|ref|WP_001273092.1|	28.0	225	518	306	4.74e-13	68.9
k141_11949_17	SARG|P42332	29.5	217	518	306	6.36e-13	68.6
k141_11949_17	SARG|ABB80128	29.5	217	518	306	6.36e-13	68.6
k141_11949_17	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.5	217	518	306	6.36e-13	68.6
k141_11949_17	SARG|gi|510143239|gb|AGN36970.1|	29.5	217	518	313	6.78e-13	68.6
k141_11949_17	SARG|ZP_04081918	27.6	225	518	306	2.75e-12	66.6
k141_11949_17	SARG|gi|445996722|ref|WP_000074577.1|	30.0	217	518	309	3.79e-12	66.2
k141_11949_17	SARG|gi|445996723|ref|WP_000074578.1|	30.0	217	518	309	5.07e-12	65.9
k141_11949_17	SARG|gi|542061059|gb|ERI11611.1|	28.1	217	518	316	5.38e-12	65.9
k141_11949_24	SARG|AE016830.1.gene424.p01	40.0	40	101	505	1.86e-06	43.5
k141_11949_25	SARG|AE016830.1.gene424.p01	62.0	71	78	505	3.00e-23	90.1
k141_11949_25	SARG|NC_002951.3237419.p01	57.7	71	78	480	4.44e-21	84.0
k141_11949_25	SARG|NC_002951.3238155.p01	51.5	68	78	465	1.38e-19	79.7
k141_11949_25	SARG|NC_002951.3237948.p01	56.3	71	78	643	5.16e-19	78.2
k141_11949_25	SARG|NC_009641.5331418.p01	50.9	55	78	452	3.80e-14	64.3
k141_11949_25	SARG|gi|498485855|ref|WP_010787543.1|	40.4	57	78	476	2.95e-09	50.4
k141_11949_25	SARG|gi|503878543|ref|WP_014112537.1|	38.6	57	78	477	7.56e-09	49.3
k141_11949_25	SARG|gi|384930133|gb|AFI26811.1|	38.6	57	78	477	7.56e-09	49.3
k141_11949_25	SARG|gi|504288593|ref|WP_014475695.1|	38.6	57	78	477	7.56e-09	49.3
k141_11949_25	SARG|ZP_03589930	38.6	57	78	477	7.56e-09	49.3
k141_11949_34	SARG|YP_002861121	51.5	68	211	212	5.61e-15	69.7
k141_11949_34	SARG|YP_001779894	50.0	68	211	212	5.51e-14	67.0
k141_11949_34	SARG|YP_001389621	48.5	68	211	212	1.46e-13	65.9
k141_11949_34	SARG|YP_001785579	48.5	68	211	212	2.79e-13	65.1
k141_11949_34	SARG|U19459.gene.p01	45.2	62	211	212	2.67e-12	62.4
k141_11949_34	NCBI|KGT34314.1|1|1|catC|catC|acetyltransferase|1|CHLORAMPHENICOL|PHENICOL|type_C_phenicol_O-acetyltransferase|AMR|phenicol	48.1	54	211	219	2.74e-11	59.7
k141_11949_34	SARG|gb|AAF63432|ARO:3003744|vatF	45.2	62	211	221	2.81e-11	59.7
k141_11949_34	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	37.5	72	211	210	8.81e-11	58.2
k141_11949_34	SARG|M58472.1.gene1.p01	42.2	64	211	209	1.20e-10	57.8
k141_11949_34	NCBI|WP_021018581.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	43.3	60	211	210	3.14e-10	56.6
k141_11949_47	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	26.5	223	287	579	2.71e-09	56.6
k141_11949_47	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	26.5	223	287	579	2.71e-09	56.6
k141_11949_47	SARG|AXF35727.1	25.9	197	287	497	3.47e-07	50.1
k141_11949_48	SARG|gi|498115003|ref|WP_010429159.1|	32.1	221	235	646	4.89e-22	93.2
k141_11949_48	SARG|gi|779793259|ref|WP_045327301.1|	32.1	221	235	646	3.05e-21	90.9
k141_11949_48	SARG|gi|1001720867|ref|WP_061274204.1|	31.7	221	235	648	3.05e-21	90.9
k141_11949_48	SARG|gi|895898290|ref|WP_048999361.1|	31.7	221	235	646	4.13e-21	90.5
k141_11949_48	SARG|gi|556337683|ref|WP_023297316.1|	29.8	228	235	646	4.13e-21	90.5
k141_11949_48	SARG|gi|751264306|ref|WP_040974017.1|	30.3	221	235	646	4.13e-21	90.5
k141_11949_48	SARG|gi|746253210|ref|WP_039301529.1|	31.2	221	235	648	4.14e-21	90.5
k141_11949_48	SARG|gi|751930065|ref|WP_041144773.1|	29.4	221	235	648	4.14e-21	90.5
k141_11949_48	SARG|gi|765031087|ref|WP_044596899.1|	31.7	221	235	646	5.61e-21	90.1
k141_11949_48	SARG|gi|695840638|ref|WP_032753940.1|	29.7	222	235	646	5.61e-21	90.1
k141_12267_8	SARG|gi|746243059|ref|WP_039291473.1|	41.9	222	234	648	1.97e-51	175
k141_12267_8	SARG|gi|495736522|ref|WP_008461101.1|	41.4	222	234	648	3.77e-50	172
k141_12267_8	SARG|gi|746253210|ref|WP_039301529.1|	41.4	222	234	648	3.77e-50	172
k141_12267_8	SARG|gi|1001720867|ref|WP_061274204.1|	41.4	222	234	648	5.23e-50	171
k141_12267_8	SARG|gi|895865878|ref|WP_048974758.1|	41.4	220	234	646	5.05e-49	169
k141_12267_8	SARG|gi|694064328|ref|WP_032410816.1|	40.5	220	234	646	1.32e-47	165
k141_12267_8	SARG|gb|AAV85982.1|ARO:3000535|macB	36.0	236	234	644	2.35e-45	159
k141_12267_8	SARG|gb|AAK76137.1|ARO:3000024|patA	27.0	233	234	564	6.44e-17	78.2
k141_12267_8	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.3	227	234	575	8.78e-17	77.8
k141_12267_8	SARG|gi|748767925|ref|WP_040019608.1|	28.8	229	234	623	5.56e-16	75.5
k141_12267_16	SARG|gb|WP_104671188.1|ARO:3003948|efrA	39.9	602	624	575	1.72e-130	394
k141_12267_16	SARG|gb|AAK76137.1|ARO:3000024|patA	33.5	555	624	564	1.24e-93	298
k141_12267_16	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.3	566	624	582	3.23e-55	196
k141_12267_16	SARG|gi|662129758|ref|WP_030081404.1|	36.6	298	624	605	5.79e-49	179
k141_12267_16	SARG|gi|695842130|ref|WP_032755430.1|	30.3	409	624	603	7.71e-49	179
k141_12267_16	SARG|gi|664085850|ref|WP_030624018.1|	36.6	298	624	605	7.93e-49	179
k141_12267_16	SARG|gi|764446018|ref|WP_044369325.1|	36.6	298	624	605	7.93e-49	179
k141_12267_16	SARG|gi|1045390184|ref|WP_065479071.1|	36.6	298	624	605	7.93e-49	179
k141_12267_16	SARG|gi|505420018|ref|WP_015607120.1|	30.3	409	624	603	1.06e-48	178
k141_12267_16	SARG|gi|664170108|ref|WP_030704355.1|	36.2	298	624	603	1.45e-48	178
k141_12267_17	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.5	522	610	664	6.27e-114	353
k141_12267_17	SARG|gb|AAK76136.1|ARO:3000025|patB	34.9	588	610	588	3.31e-113	349
k141_12267_17	SARG|gb|CDO61516.1|ARO:3003949|efrB	46.4	334	610	362	1.12e-93	291
k141_12267_17	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	32.0	600	610	579	4.29e-90	289
k141_12267_17	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	30.6	594	610	579	1.66e-89	287
k141_12267_17	SARG|gi|493394434|ref|WP_006350564.1|	32.5	570	610	602	6.53e-87	281
k141_12267_17	SARG|gi|944009777|ref|WP_055601444.1|	32.2	574	610	628	9.16e-86	279
k141_12267_17	SARG|gi|944152509|ref|WP_055644808.1|	32.3	572	610	616	7.26e-85	276
k141_12267_17	SARG|gi|1033217078|gb|OAR27197.1|	31.0	591	610	601	1.39e-84	275
k141_12267_17	SARG|gi|639892676|ref|WP_024755698.1|	32.3	572	610	631	3.95e-84	275
k141_2506_8	SARG|gb|ADV91011.1|ARO:3000245|RbpA	49.1	106	116	114	1.11e-22	84.3
k141_2506_26	SARG|gi|515720450|ref|WP_017153050.1|	35.2	108	338	210	1.65e-08	53.1
k141_2506_26	SARG|AF155139.2.gene5.p01	37.1	97	338	206	2.12e-08	52.8
k141_2506_26	SARG|gi|670466162|ref|WP_031414939.1|	34.0	97	338	206	1.05e-06	47.8
k141_2506_26	SARG|gi|1028848471|ref|WP_064017434.1|	32.6	95	338	206	2.57e-06	46.6
k141_75693_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.3	133	249	228	1.58e-07	49.7
k141_75693_7	CARD|gb|ADM92605.1|ARO:3000553|adeR	22.7	172	249	247	4.43e-07	48.5
k141_75693_7	CARD|gb|AAG05188.1|ARO:3005068|ParR	26.6	139	249	235	7.49e-07	47.8
k141_75693_7	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.6	133	249	204	7.98e-07	47.4
k141_75693_9	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.2	224	264	255	1.23e-57	183
k141_75693_9	SARG|gb|AAV85982.1|ARO:3000535|macB	44.2	224	264	644	2.66e-53	181
k141_75693_9	SARG|gi|1032819400|ref|WP_064325534.1|	43.5	216	264	646	4.85e-47	164
k141_75693_9	SARG|gi|754964360|ref|WP_042320280.1|	40.5	232	264	648	9.47e-47	164
k141_75693_34	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.7	192	402	255	4.03e-46	158
k141_75693_34	SARG|gi|516510995|ref|WP_017899433.1|	40.5	210	402	646	4.73e-39	147
k141_75693_34	SARG|gi|852125444|ref|WP_048290339.1|	40.5	210	402	646	8.84e-39	146
k141_75693_34	SARG|gi|895895864|ref|WP_048997630.1|	40.5	210	402	644	1.19e-38	145
k141_75693_34	SARG|gi|1031835425|ref|WP_064161077.1|	40.5	210	402	646	1.21e-38	145
k141_75693_34	SARG|gi|749566484|ref|WP_040196642.1|	40.5	210	402	646	1.21e-38	145
k141_75693_34	SARG|gi|644804533|ref|WP_025368306.1|	40.5	210	402	646	1.21e-38	145
k141_75693_34	SARG|gi|694091522|ref|WP_032436203.1|	40.5	210	402	646	1.21e-38	145
k141_75693_34	SARG|gi|983413012|ref|WP_060578893.1|	40.5	210	402	646	1.21e-38	145
k141_75693_34	SARG|gi|556235879|ref|WP_023284905.1|	40.5	210	402	646	1.21e-38	145
k141_7314_9	SARG|gb|ABO11759.2|ARO:3004573|Acinetobacter	31.9	432	456	429	4.38e-72	233
k141_66185_17	SARG|AF462611.1.orf0.gene.p01	34.4	192	308	281	3.91e-18	81.6
k141_76247_13	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	52.8	159	160	159	6.13e-53	164
k141_76247_25	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	47.0	432	442	444	1.25e-124	368
k141_76247_36	SARG|gi|446048013|ref|WP_000125868.1|	42.7	218	329	648	1.73e-45	162
k141_76247_36	SARG|gi|1032819400|ref|WP_064325534.1|	42.5	212	329	646	8.00e-44	158
k141_76247_36	SARG|gi|985815823|ref|WP_060876116.1|	41.3	213	329	646	1.96e-42	154
k141_76247_36	SARG|gi|754964360|ref|WP_042320280.1|	43.2	199	329	648	2.74e-42	154
k141_76247_36	SARG|gb|AAV85982.1|ARO:3000535|macB	40.1	207	329	644	6.42e-41	150
k141_76247_36	SARG|gi|860594225|ref|WP_048475168.1|	28.5	228	329	620	9.80e-13	67.8
k141_76247_36	SARG|gi|926351744|ref|WP_053683383.1|	27.7	238	329	648	1.34e-12	67.4
k141_76247_36	SARG|gi|664352659|ref|WP_030880307.1|	31.2	205	329	601	2.30e-12	66.6
k141_76247_36	SARG|gi|662754041|ref|WP_030125200.1|	31.2	205	329	601	2.30e-12	66.6
k141_76247_36	SARG|gi|664100597|ref|WP_030638327.1|	31.2	205	329	601	2.30e-12	66.6
k141_71974_12	SARG|X63451.gene.p01	31.4	226	492	550	5.24e-13	70.1
k141_71974_12	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	31.4	226	492	550	5.24e-13	70.1
k141_71974_12	SARG|M80346.gene.p01	33.2	202	492	551	6.95e-13	69.7
k141_71974_12	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	33.2	202	492	551	6.95e-13	69.7
k141_71974_12	SARG|gb|AAK76137.1|ARO:3000024|patA	27.3	209	492	564	3.61e-11	64.3
k141_71974_12	SARG|gb|ABX00624.1|ARO:3002881|lmrC	23.8	533	492	550	6.19e-11	63.5
k141_71974_12	SARG|gi|655143626|ref|WP_028590425.1|	25.7	183	492	492	5.81e-07	50.8
k141_71974_12	SARG|gi|738121094|ref|WP_036079133.1|	24.6	183	492	493	1.02e-06	50.1
k141_71974_12	SARG|gi|490350160|ref|WP_004229933.1|	25.1	183	492	493	1.78e-06	49.3
k141_71974_12	SARG|gi|496784101|ref|WP_009371362.1|	25.1	183	492	493	1.78e-06	49.3
k141_71974_81	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	43.7	229	241	228	1.01e-57	182
k141_71974_81	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.4	227	241	232	1.93e-50	163
k141_71974_81	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.6	227	241	231	3.35e-48	157
k141_71974_81	CARD|gb|AAD51348.1|ARO:3003066|smeR	39.2	237	241	229	2.52e-47	155
k141_71974_81	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.2	225	241	219	2.38e-45	150
k141_71974_81	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.8	228	241	232	5.88e-40	136
k141_71974_81	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	36.8	228	241	232	5.88e-40	136
k141_71974_81	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.7	229	241	231	2.50e-38	132
k141_71974_81	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.8	228	241	232	2.57e-38	132
k141_71974_81	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.7	229	241	231	4.96e-38	131
k141_71974_86	SARG|gi|558693259|ref|WP_023522676.1|	26.0	200	297	492	1.56e-09	57.4
k141_71974_86	SARG|gb|ABX00624.1|ARO:3002881|lmrC	28.9	194	297	550	2.95e-09	56.6
k141_71974_86	SARG|gi|1024915484|ref|WP_063548266.1|	26.0	200	297	492	3.72e-09	56.2
k141_71974_86	SARG|gi|506990141|ref|WP_016080735.1|	26.0	200	297	492	6.65e-09	55.5
k141_71974_86	SARG|gi|445983937|ref|WP_000061792.1|	26.0	200	297	492	6.65e-09	55.5
k141_71974_86	SARG|gi|445983946|ref|WP_000061801.1|	25.5	200	297	492	8.88e-09	55.1
k141_71974_86	SARG|gi|445983948|ref|WP_000061803.1|	25.5	200	297	492	8.88e-09	55.1
k141_71974_86	SARG|gi|445983947|ref|WP_000061802.1|	25.5	200	297	492	1.19e-08	54.7
k141_71974_86	SARG|gi|516373453|ref|WP_017763486.1|	25.5	200	297	492	1.19e-08	54.7
k141_71974_86	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	27.5	189	297	522	1.22e-08	54.7
k141_72122_9	SARG|gi|696368937|ref|WP_032943949.1|	43.8	219	266	648	5.69e-56	189
k141_72122_9	SARG|gi|851913025|ref|WP_048215946.1|	43.8	219	266	648	5.69e-56	189
k141_72122_9	SARG|gi|489930965|ref|WP_003834285.1|	43.8	219	266	648	5.69e-56	189
k141_72122_9	SARG|YP_002850060	43.8	219	266	648	1.10e-55	188
k141_72122_9	SARG|gi|696361545|ref|WP_032936694.1|	43.8	219	266	648	1.10e-55	188
k141_72122_9	SARG|gi|489936909|ref|WP_003840216.1|	43.8	219	266	648	1.10e-55	188
k141_72122_9	SARG|gi|507079862|ref|WP_016150620.1|	43.8	219	266	648	1.10e-55	188
k141_72122_9	SARG|gi|949791377|ref|WP_057104572.1|	43.8	219	266	648	1.10e-55	188
k141_72122_9	SARG|gi|507086196|ref|WP_016156937.1|	44.5	220	266	648	1.53e-55	187
k141_72122_9	SARG|gi|936194420|ref|WP_054528571.1|	43.8	219	266	648	2.97e-55	187
k141_8305_7	SARG|AF170880.4.gene1.p01	29.2	619	637	615	9.49e-77	255
k141_8305_7	SARG|gi|944009777|ref|WP_055601444.1|	28.5	625	637	628	3.42e-76	254
k141_8305_7	SARG|gi|558888514|ref|WP_023543283.1|	29.1	619	637	615	1.35e-75	252
k141_8305_7	SARG|gi|944152509|ref|WP_055644808.1|	28.6	612	637	616	2.69e-75	251
k141_8305_7	SARG|gi|517347347|ref|WP_018522839.1|	28.2	624	637	601	5.24e-75	250
k141_8305_7	SARG|gi|496018010|ref|WP_008742581.1|	30.1	598	637	623	6.08e-75	251
k141_8305_7	SARG|gi|947982677|ref|WP_056642336.1|	28.4	620	637	626	1.26e-74	250
k141_8305_7	SARG|gi|639892676|ref|WP_024755698.1|	28.4	612	637	631	7.32e-74	248
k141_8305_7	SARG|gi|516795764|ref|WP_018105258.1|	28.3	611	637	601	7.46e-74	247
k141_8305_7	SARG|gi|695865802|ref|WP_032778631.1|	28.6	619	637	605	8.14e-74	247
k141_8305_8	SARG|gi|639892676|ref|WP_024755698.1|	37.1	582	603	631	4.96e-108	337
k141_8305_8	SARG|gi|948137056|ref|WP_056795395.1|	36.5	581	603	602	8.85e-108	335
k141_8305_8	SARG|gi|947982677|ref|WP_056642336.1|	36.9	582	603	626	1.21e-107	336
k141_8305_8	SARG|gi|928900436|ref|WP_053931243.1|	36.3	581	603	600	4.62e-107	333
k141_8305_8	SARG|gi|664579989|ref|WP_031094015.1|	36.3	581	603	601	4.75e-107	333
k141_8305_8	SARG|gi|505420018|ref|WP_015607120.1|	36.2	580	603	603	5.01e-107	333
k141_8305_8	SARG|gi|664556405|ref|WP_031071225.1|	36.2	580	603	602	9.66e-107	333
k141_8305_8	SARG|gi|944152509|ref|WP_055644808.1|	37.1	580	603	616	1.00e-106	333
k141_8305_8	SARG|gi|739906046|ref|WP_037756452.1|	36.3	570	603	620	1.57e-106	333
k141_8305_8	SARG|gi|516574297|ref|WP_017949361.1|	36.3	570	603	620	1.57e-106	333
k141_72469_12	SARG|gi|542061059|gb|ERI11611.1|	28.4	229	264	316	3.10e-19	84.3
k141_72469_12	SARG|gb|AAK76137.1|ARO:3000024|patA	28.8	229	264	564	5.91e-15	73.2
k141_72469_16	SARG|L42544.gene.p01	27.3	620	752	651	2.52e-57	206
k141_72469_16	SARG|AAV80410	27.1	620	752	651	3.12e-56	202
k141_72469_16	SARG|AAY62597	27.0	725	752	639	4.85e-56	202
k141_72469_16	SARG|FN594949.1.gene24.p01	25.5	718	752	640	2.37e-55	200
k141_72469_16	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	25.5	718	752	640	4.44e-55	199
k141_72469_16	SARG|YP_002850805	28.3	621	752	652	1.66e-53	195
k141_72469_16	SARG|ZP_02952732	28.4	620	752	652	2.26e-53	194
k141_72469_16	SARG|ZP_02632674	28.4	620	752	660	2.54e-53	194
k141_72469_16	SARG|L20800.gene.p01	28.4	620	752	652	4.22e-53	194
k141_72469_16	SARG|NP_348076	27.2	622	752	652	3.25e-51	188
k141_72469_24	SARG|gi|921979807|ref|WP_053271336.1|	30.4	230	254	648	5.70e-17	79.0
k141_72469_24	SARG|gi|817122037|ref|WP_046494699.1|	30.8	214	254	613	5.58e-14	70.1
k141_72469_24	SARG|gi|860594225|ref|WP_048475168.1|	31.3	201	254	620	1.85e-13	68.6
k141_72469_24	SARG|gi|496018010|ref|WP_008742581.1|	30.3	208	254	623	2.50e-13	68.2
k141_72469_24	SARG|gi|944470764|ref|WP_055701183.1|	30.7	215	254	601	3.33e-13	67.8
k141_72469_24	SARG|gi|926400371|ref|WP_053728483.1|	31.1	212	254	603	3.33e-13	67.8
k141_72469_24	SARG|gi|953808775|ref|WP_058042812.1|	29.2	236	254	608	3.34e-13	67.8
k141_72469_24	SARG|gi|947982677|ref|WP_056642336.1|	29.7	222	254	626	3.38e-13	67.8
k141_72469_24	SARG|gi|639892676|ref|WP_024755698.1|	29.7	222	254	631	3.39e-13	67.8
k141_72469_24	SARG|gb|AAK76137.1|ARO:3000024|patA	29.0	169	254	564	4.37e-13	67.4
k141_72469_45	SARG|gi|757709471|ref|WP_042938492.1|	37.2	218	811	646	4.74e-28	119
k141_72469_45	SARG|gi|554689873|ref|WP_023186409.1|	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|446048048|ref|WP_000125903.1|	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|Q57R58	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|959109145|ref|WP_058113944.1|	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|555258323|ref|WP_023240896.1|	36.6	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|554685678|ref|WP_023185565.1|	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|555271393|ref|WP_023251561.1|	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|554922094|ref|WP_023194682.1|	37.0	227	811	648	3.46e-27	116
k141_72469_45	SARG|gi|446048047|ref|WP_000125902.1|	37.0	227	811	648	3.46e-27	116
k141_72469_50	SARG|gi|740152780|ref|WP_037997109.1|	26.0	181	329	322	8.78e-13	67.0
k141_72469_50	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	33.7	104	329	323	3.10e-11	62.4
k141_72469_51	SARG|CP003583.1.gene510.p01	35.2	423	486	457	4.07e-71	232
k141_72469_51	SARG|gi|1036324608|gb|OAZ67878.1|	31.6	411	486	477	1.91e-46	167
k141_72469_51	SARG|gi|566055109|gb|AHC40857.1|	30.2	463	486	477	2.65e-46	166
k141_72469_51	SARG|gi|384930133|gb|AFI26811.1|	32.4	413	486	477	3.67e-46	166
k141_72469_51	SARG|gi|1030030526|gb|ANF35167.1|	31.9	411	486	477	3.67e-46	166
k141_72469_51	SARG|gi|371566923|emb|CCF03773.1|	31.9	411	486	477	5.08e-46	166
k141_72469_51	SARG|gi|494883168|ref|WP_007609218.1|	31.9	411	486	479	5.26e-46	166
k141_72469_51	SARG|gi|1007411670|gb|AMQ72759.1|	32.2	413	486	477	7.03e-46	165
k141_72469_51	SARG|gi|393806119|gb|EJD67473.1|	32.2	413	486	477	9.74e-46	165
k141_72469_51	SARG|gi|503878543|ref|WP_014112537.1|	32.9	413	486	477	1.87e-45	164
k141_66625_28	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	92.9	1184	1188	1186	0.0	2196
k141_66625_28	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	92.9	1184	1188	1186	0.0	2196
k141_66625_28	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	65.3	1145	1188	1162	0.0	1480
k141_66625_52	SARG|gi|446048013|ref|WP_000125868.1|	40.8	223	396	648	1.16e-42	157
k141_66625_52	SARG|gi|757782629|ref|WP_043001213.1|	39.9	223	396	648	2.20e-42	156
k141_66625_52	SARG|gi|992390012|ref|WP_061077002.1|	39.9	223	396	648	2.20e-42	156
k141_66625_52	SARG|gi|763407609|ref|WP_044264203.1|	39.9	223	396	648	2.20e-42	156
k141_66625_52	SARG|gi|754927849|ref|WP_042284850.1|	39.9	223	396	648	2.20e-42	156
k141_66625_52	SARG|gi|968563772|ref|WP_058587854.1|	39.9	223	396	648	3.01e-42	155
k141_66625_52	SARG|gi|817104523|ref|WP_046477871.1|	40.4	223	396	648	3.01e-42	155
k141_66625_52	SARG|gi|502669352|ref|WP_012905216.1|	39.5	223	396	648	3.01e-42	155
k141_66625_52	SARG|gi|754964360|ref|WP_042320280.1|	40.8	223	396	648	3.01e-42	155
k141_66625_52	SARG|gi|764278838|ref|WP_044327089.1|	40.4	223	396	648	3.01e-42	155
k141_66625_59	SARG|gi|803568669|ref|WP_046077412.1|	41.2	216	277	648	2.11e-41	149
k141_66625_59	SARG|gi|446110352|ref|WP_000188207.1|	41.2	216	277	648	2.11e-41	149
k141_66625_59	SARG|YP_002382193	41.2	216	277	648	2.11e-41	149
k141_66625_59	SARG|gi|803575554|ref|WP_046081557.1|	41.2	216	277	648	2.11e-41	149
k141_66625_59	SARG|gi|446110351|ref|WP_000188206.1|	41.2	216	277	648	2.11e-41	149
k141_66625_59	SARG|gi|757799695|ref|WP_043016897.1|	38.3	248	277	648	2.91e-41	149
k141_66625_59	SARG|gi|696368937|ref|WP_032943949.1|	38.3	248	277	648	5.51e-41	148
k141_66625_59	SARG|gi|851913025|ref|WP_048215946.1|	38.3	248	277	648	5.51e-41	148
k141_66625_59	SARG|gi|489930965|ref|WP_003834285.1|	38.3	248	277	648	5.51e-41	148
k141_66625_59	SARG|gi|489936909|ref|WP_003840216.1|	38.3	248	277	648	7.58e-41	148
k141_67221_28	SARG|gi|671541568|ref|WP_031525212.1|	32.4	108	1010	648	1.74e-08	57.4
k141_9539_10	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.7	107	218	228	2.06e-07	48.9
k141_9539_13	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	35.9	312	328	343	2.59e-60	195
k141_9539_13	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	32.5	308	328	325	1.56e-49	167
k141_9539_13	SARG|gb|AAA26793|ARO:3003748|oleC	32.4	306	328	325	3.09e-49	166
k141_9539_13	SARG|gb|AAR96051.1|ARO:3002894|otrC	29.4	316	328	351	1.15e-30	117
k141_9539_13	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	29.4	316	328	351	1.15e-30	117
k141_9539_13	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.6	216	328	258	6.25e-21	89.4
k141_9539_13	SARG|gb|AAK76137.1|ARO:3000024|patA	26.6	203	328	564	6.44e-15	74.3
k141_9539_13	SARG|gb|APB03219.1|ARO:3003986|TaeA	24.2	231	328	648	2.38e-09	57.4
k141_9539_28	SARG|gi|803568669|ref|WP_046077412.1|	44.4	108	323	648	6.45e-20	89.4
k141_9539_28	SARG|gi|446110352|ref|WP_000188207.1|	44.4	108	323	648	6.45e-20	89.4
k141_9539_28	SARG|YP_002382193	44.4	108	323	648	6.45e-20	89.4
k141_9539_28	SARG|gi|803575554|ref|WP_046081557.1|	44.4	108	323	648	6.45e-20	89.4
k141_9539_28	SARG|gi|446110351|ref|WP_000188206.1|	44.4	108	323	648	6.45e-20	89.4
k141_9539_28	SARG|gi|736472622|ref|WP_034494292.1|	43.5	108	323	648	1.17e-19	88.6
k141_9539_28	SARG|gi|1035670474|ref|WP_064517458.1|	42.6	108	323	648	2.85e-19	87.4
k141_9539_28	SARG|gi|1035717981|ref|WP_064557480.1|	42.6	108	323	648	2.85e-19	87.4
k141_9539_28	SARG|gi|1035706844|ref|WP_064548272.1|	43.5	108	323	648	2.85e-19	87.4
k141_9539_28	SARG|gb|AAV85982.1|ARO:3000535|macB	35.2	108	323	644	6.76e-14	71.2
k141_9539_68	SARG|gi|1004359922|gb|AMP42228.1|	25.5	440	627	639	5.76e-22	99.4
k141_9539_68	SARG|gi|164612278|gb|ABY63608.1|	24.1	432	627	639	1.27e-20	95.1
k141_9539_68	SARG|ABB70049	24.1	432	627	639	1.27e-20	95.1
k141_9539_68	SARG|ABN80187	25.2	440	627	640	1.28e-20	95.1
k141_9539_68	SARG|ABP89888	24.1	432	627	644	1.29e-20	95.1
k141_9539_68	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.8	440	627	629	1.65e-20	94.7
k141_9539_68	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	24.8	440	627	629	1.65e-20	94.7
k141_9539_68	ResF|tet(O/W)_3_AM889120_1	24.8	440	627	639	1.69e-20	94.7
k141_9539_68	ResF|tet(O/W)_4_AM889121_1	24.8	440	627	639	1.69e-20	94.7
k141_9539_68	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.5	440	627	629	5.08e-20	93.2
k141_9539_73	SARG|gi|488374619|ref|WP_002444004.1|	37.8	143	162	452	8.55e-32	117
k141_9539_73	SARG|gi|1006223553|ref|WP_061745579.1|	35.0	143	162	451	1.13e-29	111
k141_9539_73	SARG|gi|686448604|ref|WP_031928572.1|	35.0	143	162	451	1.13e-29	111
k141_9539_73	SARG|gi|537465183|ref|WP_020976941.1|	35.0	143	162	451	2.17e-29	110
k141_9539_73	SARG|gi|686408548|ref|WP_031913080.1|	35.0	143	162	451	2.17e-29	110
k141_9539_73	SARG|gi|686432388|ref|WP_031921070.1|	35.0	143	162	451	2.17e-29	110
k141_9539_73	SARG|ZP_03986195	35.0	143	162	451	2.17e-29	110
k141_9539_73	SARG|gi|446573715|ref|WP_000651061.1|	35.0	143	162	451	2.17e-29	110
k141_9539_73	SARG|gi|446573693|ref|WP_000651039.1|	35.0	143	162	451	2.17e-29	110
k141_9539_73	SARG|gi|446573692|ref|WP_000651038.1|	35.0	143	162	451	2.17e-29	110
k141_9539_93	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	71.0	307	308	307	8.35e-154	431
k141_9539_93	SARG|gi|445996708|ref|WP_000074563.1|	56.2	299	308	309	3.83e-107	313
k141_9539_93	SARG|gi|488042066|ref|WP_002113463.1|	55.5	299	308	309	8.86e-106	310
k141_9539_93	SARG|YP_001373621	54.2	299	308	318	1.69e-105	309
k141_9539_93	SARG|gi|445996719|ref|WP_000074574.1|	54.8	299	308	309	2.52e-105	308
k141_9539_93	SARG|gi|445996710|ref|WP_000074565.1|	54.8	299	308	309	5.07e-105	308
k141_9539_93	SARG|gi|895736250|emb|COF64653.1|	54.8	299	308	309	1.02e-104	307
k141_9539_93	SARG|gi|488053456|ref|WP_002124853.1|	54.3	302	308	309	1.02e-104	307
k141_9539_93	SARG|gi|445996714|ref|WP_000074569.1|	54.8	299	308	309	1.02e-104	307
k141_9539_93	SARG|gi|895808656|emb|COR83787.1|	54.8	299	308	309	1.02e-104	307
k141_9539_94	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.0	275	308	359	8.41e-32	120
k141_9539_94	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.6	308	308	364	1.24e-29	114
k141_9539_94	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.6	308	308	364	1.24e-29	114
k141_9539_94	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.8	264	308	370	3.62e-29	113
k141_9539_94	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.6	283	308	365	8.93e-29	112
k141_9539_94	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.1	299	308	392	3.44e-28	111
k141_9539_94	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.4	285	308	380	1.07e-27	109
k141_9539_94	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.4	285	308	380	1.07e-27	109
k141_9539_94	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.2	309	308	381	2.85e-27	108
k141_9539_94	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.2	309	308	381	2.85e-27	108
k141_9539_95	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	38.0	229	231	229	1.76e-61	191
k141_9539_95	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.4	229	231	231	5.32e-61	190
k141_9539_95	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.0	229	231	231	1.07e-60	189
k141_9539_95	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	38.4	229	231	231	2.14e-60	188
k141_9539_95	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.0	229	231	231	4.29e-60	187
k141_9539_95	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.0	229	231	231	6.07e-60	187
k141_9539_95	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.0	230	231	230	1.18e-59	186
k141_9539_95	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.9	231	231	232	3.26e-57	180
k141_9539_95	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.2	233	231	233	4.75e-57	180
k141_9539_95	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.5	231	231	232	1.48e-55	176
k141_9539_125	SARG|gi|542061059|gb|ERI11611.1|	28.8	215	283	316	4.40e-16	75.9
k141_9539_125	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	29.8	208	283	293	4.80e-16	75.5
k141_9539_125	SARG|gi|447195835|ref|WP_001273091.1|	30.3	201	283	306	7.47e-16	75.1
k141_9539_125	SARG|gi|446026113|ref|WP_000103968.1|	28.0	218	283	306	7.47e-16	75.1
k141_9539_125	SARG|ZP_04081918	29.9	201	283	306	1.39e-15	74.3
k141_9539_125	SARG|gi|507044560|ref|WP_016115614.1|	28.0	218	283	306	1.39e-15	74.3
k141_9539_125	SARG|gi|500448961|gb|EOP61695.1|	27.0	215	283	306	1.90e-15	73.9
k141_9539_125	SARG|gi|500465078|gb|EOP76697.1|	27.0	215	283	306	1.90e-15	73.9
k141_9539_125	SARG|gi|447195836|ref|WP_001273092.1|	29.9	201	283	306	1.90e-15	73.9
k141_9539_125	SARG|gi|500194536|ref|WP_011867743.1|	29.8	218	283	306	4.81e-15	72.8
k141_78069_6	SARG|gi|694113840|ref|WP_032455777.1|	34.6	107	835	646	4.50e-09	58.9
k141_78069_6	SARG|gi|556195652|ref|WP_023279140.1|	34.6	107	835	646	4.50e-09	58.9
k141_78069_6	SARG|gi|490295685|ref|WP_004191149.1|	34.6	107	835	646	4.50e-09	58.9
k141_78069_6	SARG|gi|852125444|ref|WP_048290339.1|	34.6	107	835	646	4.50e-09	58.9
k141_78069_6	SARG|gi|1033064422|ref|WP_064375412.1|	31.6	136	835	648	4.50e-09	58.9
k141_78069_6	SARG|gi|1044231927|emb|SBX14918.1|	33.6	107	835	646	5.92e-09	58.5
k141_78069_6	SARG|gi|1046630742|ref|WP_065696754.1|	34.6	107	835	646	5.92e-09	58.5
k141_78069_6	SARG|gi|695840638|ref|WP_032753940.1|	36.3	91	835	646	7.79e-09	58.2
k141_78069_6	SARG|gi|1031824807|ref|WP_064152164.1|	36.3	91	835	646	7.79e-09	58.2
k141_78069_6	SARG|gi|556476567|ref|WP_023328168.1|	33.6	107	835	641	1.02e-08	57.8
k141_78069_9	SARG|YP_002861121	47.1	51	224	212	7.35e-10	55.8
k141_78069_9	SARG|YP_001389621	47.1	51	224	212	2.57e-09	54.3
k141_78069_9	SARG|YP_001779894	45.1	51	224	212	6.55e-09	53.1
k141_78069_9	SARG|gb|AAF63432|ARO:3003744|vatF	36.8	68	224	221	2.46e-08	51.6
k141_78069_9	SARG|YP_001785579	43.1	51	224	212	3.09e-08	51.2
k141_78069_9	SARG|U19459.gene.p01	36.7	60	224	212	7.80e-08	50.1
k141_78069_9	SARG|GQ205627.2.gene3.p01	30.0	110	224	216	1.10e-07	49.7
k141_78069_9	SARG|AF015628.1.gene2.p01	26.7	120	224	212	4.92e-07	47.8
k141_78069_9	SARG|AF139725.gene.p01	42.9	49	224	214	2.29e-06	45.8
k141_78069_9	SARG|AAF24171	42.9	49	224	214	2.29e-06	45.8
k141_78069_10	SARG|YP_002861121	37.1	70	88	212	7.19e-13	60.1
k141_78069_10	SARG|YP_001779894	37.3	67	88	212	7.37e-12	57.4
k141_78069_10	SARG|YP_001389621	35.8	67	88	212	1.99e-11	56.2
k141_78069_10	SARG|YP_001785579	35.8	67	88	212	3.86e-11	55.5
k141_78069_10	SARG|U19459.gene.p01	36.5	52	88	212	3.87e-10	52.8
k141_78069_10	SARG|gb|AAF63432|ARO:3003744|vatF	46.9	49	88	221	5.78e-10	52.4
k141_78069_10	SARG|AF139725.gene.p01	44.0	50	88	214	7.59e-10	52.0
k141_78069_10	SARG|AAF24171	44.0	50	88	214	7.59e-10	52.0
k141_78069_10	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	44.0	50	88	214	7.59e-10	52.0
k141_78069_10	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	44.0	50	88	214	7.59e-10	52.0
k141_78069_20	SARG|gi|815842605|ref|WP_046464285.1|	29.9	127	460	388	1.79e-06	48.9
k141_67570_3	SARG|gi|922960663|ref|WP_053388845.1|	28.3	219	538	648	1.11e-20	94.7
k141_67570_3	SARG|gi|757799695|ref|WP_043016897.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|1045891604|ref|WP_065554100.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|507082903|ref|WP_016153652.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|696368937|ref|WP_032943949.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|851913025|ref|WP_048215946.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|740856590|ref|WP_038641842.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|507086196|ref|WP_016156937.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|489930965|ref|WP_003834285.1|	28.3	219	538	648	1.47e-20	94.4
k141_67570_3	SARG|gi|835233765|ref|WP_047410073.1|	28.3	219	538	648	2.60e-20	93.6
k141_67570_7	SARG|AAA50325	31.8	519	534	569	1.42e-69	232
k141_67570_7	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	494	534	655	1.14e-67	229
k141_67570_7	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	494	534	655	1.14e-67	229
k141_67570_7	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.6	494	534	655	1.58e-67	229
k141_67570_7	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	491	534	655	3.07e-67	228
k141_67570_7	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	494	534	655	3.07e-67	228
k141_67570_7	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	494	534	655	4.26e-67	228
k141_67570_7	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	494	534	655	4.26e-67	228
k141_67570_7	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.4	494	534	655	4.26e-67	228
k141_67570_7	SARG|gb|AKA86814|ARO:3003746|optrA	30.4	494	534	655	4.26e-67	228
k141_67570_13	SARG|VXQ21601.1	36.5	340	390	344	3.50e-58	192
k141_67570_13	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	36.4	341	390	379	8.71e-58	192
k141_67570_13	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	36.4	341	390	416	1.54e-57	192
k141_67570_13	SARG|CP001581.1.gene3143.p01	35.1	336	390	344	8.75e-55	183
k141_67570_13	SARG|gb|ACX65640.1|ARO:3003907|cipA	35.2	335	390	346	9.21e-55	183
k141_67570_13	SARG|gb|CAL84423.1|ARO:3004146|cfrC	35.3	337	390	344	4.78e-54	181
k141_67570_13	NCBI|WP_002349981.1|1|1|cfr(B)|cfr(B)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/LINEZOLID/RETAPAMULIN/STREPTOGRAMIN_B/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(B)|AMR|multidrug	34.0	332	390	349	5.83e-53	178
k141_67570_13	SARG|gb|CDF47262.1|ARO:3004649|cfr(B)	34.0	332	390	349	5.83e-53	178
k141_67570_13	SARG|gb|AIX48090.1|ARO:3004599|clcD	33.7	332	390	349	2.26e-52	177
k141_67570_13	SARG|gb|BAD63613.1|ARO:3002816|clbC	32.4	361	390	350	3.25e-52	176
k141_67570_53	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	52.8	769	773	703	6.25e-264	745
k141_67570_57	CARD|gb|WKR28567.1|ARO:3007678|IreK	29.3	768	758	718	8.54e-71	244
k141_67570_82	CARD|gb|BAB36671.1|ARO:3000832|evgA	29.8	198	253	204	4.24e-19	81.6
k141_67570_82	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	29.6	115	253	228	6.36e-12	62.4
k141_67570_82	CARD|gb|ATC67679.1|ARO:3000838|arlR	21.4	140	253	219	3.34e-08	51.6
k141_67570_94	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.1	235	670	579	2.00e-18	88.2
k141_67570_94	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.1	235	670	579	4.63e-18	87.0
k141_67570_105	SARG|CAB12101	28.8	170	213	512	1.23e-14	70.9
k141_67570_105	SARG|ZP_03053667	28.1	167	213	506	2.25e-14	70.1
k141_67570_105	SARG|YP_001486998	28.1	167	213	530	3.11e-14	69.7
k141_67570_105	SARG|YP_001419960	26.7	172	213	510	1.03e-13	68.2
k141_67570_114	SARG|gi|639225329|ref|WP_024561799.1|	38.4	297	949	648	2.21e-48	182
k141_67570_114	SARG|gi|976146774|ref|WP_059305359.1|	38.6	293	949	648	2.21e-48	182
k141_67570_114	SARG|gi|639218559|ref|WP_024556062.1|	38.4	297	949	648	2.21e-48	182
k141_67570_114	SARG|gi|657888313|ref|WP_029592374.1|	38.8	291	949	648	2.98e-48	181
k141_67570_114	SARG|gi|895981299|ref|WP_049056431.1|	38.2	293	949	648	2.98e-48	181
k141_67570_114	SARG|gi|823281237|ref|WP_047037467.1|	38.2	293	949	648	2.98e-48	181
k141_67570_114	SARG|gi|779903733|ref|WP_045374054.1|	38.2	293	949	648	2.98e-48	181
k141_67570_114	SARG|gi|823326845|ref|WP_047080664.1|	38.2	293	949	648	4.01e-48	181
k141_67570_114	SARG|gi|895967513|ref|WP_049046752.1|	38.2	293	949	648	4.01e-48	181
k141_67570_114	SARG|gi|1022664304|ref|WP_063420886.1|	38.8	294	949	648	5.40e-48	181
k141_67570_115	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	36.7	226	312	346	1.06e-22	95.5
k141_67570_135	SARG|gi|507086196|ref|WP_016156937.1|	32.2	236	570	648	1.08e-22	101
k141_67570_135	SARG|gi|740856590|ref|WP_038641842.1|	31.8	236	570	648	2.52e-22	100
k141_67570_135	SARG|gi|757799695|ref|WP_043016897.1|	31.8	236	570	648	3.35e-22	99.8
k141_67570_135	SARG|gi|1045891604|ref|WP_065554100.1|	31.8	236	570	648	3.35e-22	99.8
k141_67570_135	SARG|gi|507082903|ref|WP_016153652.1|	31.8	236	570	648	3.35e-22	99.8
k141_67570_135	SARG|gi|922960663|ref|WP_053388845.1|	32.6	236	570	648	3.35e-22	99.8
k141_67570_135	SARG|gi|923061916|ref|WP_053445667.1|	32.5	243	570	648	3.35e-22	99.8
k141_67570_135	SARG|gi|835233765|ref|WP_047410073.1|	31.8	236	570	648	4.45e-22	99.4
k141_67570_135	SARG|gi|754951242|ref|WP_042307417.1|	31.8	236	570	648	4.45e-22	99.4
k141_67570_135	SARG|gi|493734654|ref|WP_006683876.1|	31.8	236	570	648	4.45e-22	99.4
k141_67570_156	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	29.2	469	484	481	1.01e-45	165
k141_67570_156	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	29.9	471	484	451	2.14e-45	163
k141_67570_156	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	30.1	468	484	451	7.70e-44	159
k141_67570_162	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	34.7	737	760	722	3.27e-87	289
k141_67570_163	SARG|gi|498515089|ref|WP_010815296.1|	31.9	251	400	323	2.02e-25	104
k141_67570_163	SARG|Q47748	31.9	251	400	323	2.77e-25	103
k141_67570_163	SARG|gi|985522333|ref|WP_060811962.1|	31.9	251	400	323	2.77e-25	103
k141_67570_163	SARG|gb|AAB05626.1|ARO:3002943|vanHB	31.5	251	400	323	3.80e-25	103
k141_67570_163	SARG|gi|740152780|ref|WP_037997109.1|	31.5	257	400	322	5.13e-25	103
k141_67570_163	SARG|YP_002333394	31.5	251	400	323	1.67e-23	99.0
k141_67570_163	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	31.5	251	400	323	1.67e-23	99.0
k141_67570_163	SARG|AF310956.2.gene5.p01	31.5	251	400	323	2.29e-23	98.6
k141_67570_163	SARG|gi|749574782|ref|WP_040203616.1|	30.0	260	400	323	8.01e-23	97.1
k141_67570_163	SARG|DQ018711.1.gene4.p01	29.0	286	400	322	1.08e-22	96.7
k141_57797_4	SARG|NC_002951.3237948.p01	36.2	428	549	643	3.00e-83	271
k141_57797_4	SARG|AE016830.1.gene424.p01	35.3	442	549	505	8.99e-82	263
k141_57797_4	SARG|NC_002951.3237419.p01	32.8	472	549	480	2.92e-79	256
k141_57797_4	SARG|NC_002951.3238155.p01	33.3	414	549	465	6.09e-72	236
k141_57797_4	SARG|NC_009641.5331418.p01	33.3	403	549	452	4.89e-70	231
k141_57797_4	SARG|gi|1030030526|gb|ANF35167.1|	29.7	474	549	477	9.83e-58	199
k141_57797_4	SARG|gi|631799622|gb|AHZ14287.1|	30.1	425	549	477	1.37e-57	198
k141_57797_4	SARG|gi|393806119|gb|EJD67473.1|	29.2	473	549	477	1.37e-57	198
k141_57797_4	SARG|gi|1044618389|gb|OCB92939.1|	29.4	473	549	477	1.37e-57	198
k141_57797_4	SARG|gi|1007411670|gb|AMQ72759.1|	29.2	473	549	477	2.65e-57	197
k141_57797_16	SARG|gi|827013130|ref|WP_047175495.1|	27.9	578	1354	603	6.63e-41	159
k141_57797_16	SARG|gi|695891735|ref|WP_032792824.1|	27.9	578	1354	603	6.63e-41	159
k141_57797_16	SARG|gi|913055317|ref|WP_050357634.1|	27.9	578	1354	603	8.89e-41	159
k141_57797_16	SARG|gi|948040364|ref|WP_056699531.1|	27.9	578	1354	603	8.89e-41	159
k141_57797_16	SARG|gi|951183771|ref|WP_057661487.1|	28.0	578	1354	603	1.59e-40	158
k141_57797_16	SARG|gi|516795764|ref|WP_018105258.1|	27.2	603	1354	601	5.00e-40	157
k141_57797_16	SARG|gi|497748188|ref|WP_010062372.1|	27.6	573	1354	605	5.26e-40	157
k141_57797_16	SARG|gi|695865802|ref|WP_032778631.1|	27.4	573	1354	605	5.26e-40	157
k141_57797_16	SARG|gi|655413091|ref|WP_028811890.1|	36.9	309	1354	603	6.87e-40	156
k141_57797_16	SARG|gi|943909899|ref|WP_055545300.1|	35.2	310	1354	601	2.15e-39	155
k141_49179_3	SARG|gi|921979807|ref|WP_053271336.1|	28.8	229	514	648	1.68e-20	94.0
k141_49179_3	SARG|gi|639209604|ref|WP_024547784.1|	29.1	227	514	648	6.76e-19	89.0
k141_49179_3	SARG|gi|445996710|ref|WP_000074565.1|	31.5	219	514	309	2.24e-16	79.0
k141_49179_3	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	22.1	524	514	655	3.41e-16	80.5
k141_49179_3	SARG|P42332	30.6	219	514	306	3.91e-16	78.2
k141_49179_3	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	30.6	219	514	306	3.91e-16	78.2
k141_49179_3	SARG|gi|895736250|emb|COF64653.1|	31.1	219	514	309	4.05e-16	78.2
k141_49179_3	SARG|gi|446110087|ref|WP_000187942.1|	31.1	219	514	309	4.05e-16	78.2
k141_49179_3	SARG|gi|445996714|ref|WP_000074569.1|	31.1	219	514	309	4.05e-16	78.2
k141_49179_3	SARG|gi|510143239|gb|AGN36970.1|	30.6	219	514	313	4.24e-16	78.2
k141_49179_6	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.5	262	566	382	8.01e-21	93.6
k141_49179_6	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.5	262	566	382	8.01e-21	93.6
k141_49179_6	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.5	262	566	384	1.16e-19	90.1
k141_49179_6	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	27.5	262	566	384	1.16e-19	90.1
k141_49179_6	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.5	262	566	386	2.84e-19	89.0
k141_49179_6	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	27.5	262	566	386	2.84e-19	89.0
k141_49179_6	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	27.1	262	566	388	2.89e-19	89.0
k141_49179_6	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.1	262	566	388	2.89e-19	89.0
k141_49179_6	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	26.7	262	566	386	9.15e-19	87.4
k141_49179_6	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.7	262	566	386	9.15e-19	87.4
k141_49179_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	49.4	235	241	228	8.32e-75	225
k141_49179_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.1	235	241	231	6.62e-51	164
k141_49179_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.6	237	241	232	9.64e-51	164
k141_49179_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.6	237	241	232	9.64e-51	164
k141_49179_7	CARD|gb|AAG05188.1|ARO:3005068|ParR	37.9	235	241	235	5.30e-48	157
k141_49179_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.5	233	241	219	5.33e-47	154
k141_49179_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.3	242	241	232	2.44e-45	150
k141_49179_7	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.3	233	241	231	8.31e-43	144
k141_49179_7	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.9	233	241	231	1.17e-42	143
k141_49179_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.5	232	241	219	9.38e-42	140
k141_49179_17	SARG|gb|AAV85982.1|ARO:3000535|macB	39.1	225	281	644	3.18e-41	149
k141_49179_17	SARG|gi|639216333|ref|WP_024554080.1|	39.8	226	281	648	2.05e-39	144
k141_49179_17	SARG|gi|896325272|ref|WP_049294291.1|	39.8	221	281	648	1.89e-38	141
k141_49179_17	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.1	219	281	579	1.13e-17	81.6
k141_49179_17	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.8	222	281	579	5.03e-17	79.7
k141_49179_17	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	27.9	208	281	528	4.04e-11	62.0
